Objective: To conduct a review of studies evaluating the influence of body size and weight (WT) on the pharmacokinetics (PK) of drugs recommended for heart failure (HF) treatment.
Data sources: A systematic search of the MEDLINE (1946 to April 2023) and EMBASE (1974 to April 2023) databases was conducted for articles that focused on the impact of WT or body size on the PK of drugs of interest used in HF patients.
Study selection and data extraction: Articles written in English or French related to the aim of our study were retained for analysis.
Data synthesis: Of 6493 articles, 20 were retained for analysis. Weight was associated with the clearance of digoxin, carvedilol, enalapril, and candesartan as well as the volume of distribution of eplerenone and bisoprolol. There was no documented direct impact of WT on the PK of furosemide, valsartan, and metoprolol, although these studies were limited or confounded by the small sample size, adjustment of PK factors by WT, or the use of the Cockroff-Gault equation for the evaluation of creatinine clearance, which includes WT.
Relevance to patient care and clinical practice: This review highlights and summarizes the available data on the importance of WT on the PK of HF treatment.
Conclusion: Considering the significant impact of WT on most HF drugs in this review, it may be important to further investigate it in the context of personalized therapy, particularly in patients presenting extreme WTs.
Keywords: ACE inhibitors; angiotensin receptor blockers; beta-blockers; body mass index; cardiac glycosides; heart failure; loop-diuretics; mineralocorticoid receptor antagonists; pharmacokinetics; weight.